ONKURE THERAPEUTICS INC CLASS A (OKUR) — insider trading
Health Care · NASDAQ
ONKURE THERAPEUTICS INC CLASS A (OKUR) has 48 reported SEC Form 4 insider transactions in our data, including 4 open-market sales among the most recent 48 (latest 2026-09-21).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | Saccomano Nicholas A | Director, Officer (President and CEO) | Open-market sale | 87 | $2.97 | $259 | Form 4 |
| 2026-09-21 | Leverone Jason A. | Officer (Chief Financial Officer) | Open-market sale | 302 | $2.97 | $898 | Form 4 |
| 2026-08-07 | Agresta Samuel | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 131,396 | — | — | Form 4 |
| 2026-08-07 | Agresta Samuel | Officer (Chief Medical Officer) | Disposition to the issuer (derivative) | 131,396 | — | — | Form 4 |
| 2026-08-07 | Agresta Samuel | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 18,588 | — | — | Form 4 |
| 2026-08-07 | Agresta Samuel | Officer (Chief Medical Officer) | Disposition to the issuer (derivative) | 18,588 | — | — | Form 4 |
| 2026-08-07 | Agresta Samuel | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-08-07 | Hartley Dylan | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 137,603 | — | — | Form 4 |
| 2026-08-07 | Hartley Dylan | Officer (Chief Scientific Officer) | Disposition to the issuer (derivative) | 137,603 | — | — | Form 4 |
| 2026-08-07 | Hartley Dylan | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-08-07 | Leverone Jason A. | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 130,611 | — | — | Form 4 |
| 2026-08-07 | Leverone Jason A. | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 130,611 | — | — | Form 4 |
| 2026-08-07 | Leverone Jason A. | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 5,322 | — | — | Form 4 |
| 2026-08-07 | Leverone Jason A. | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 5,322 | — | — | Form 4 |
| 2026-08-07 | Leverone Jason A. | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 5,781 | — | — | Form 4 |
| 2026-08-07 | Leverone Jason A. | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 5,781 | — | — | Form 4 |
| 2026-08-07 | Leverone Jason A. | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-08-07 | Saccomano Nicholas A | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 542,232 | — | — | Form 4 |
| 2026-08-07 | Saccomano Nicholas A | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 542,232 | — | — | Form 4 |
| 2026-08-07 | Saccomano Nicholas A | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 16,898 | — | — | Form 4 |
| 2026-08-07 | Saccomano Nicholas A | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 16,898 | — | — | Form 4 |
| 2026-08-07 | Saccomano Nicholas A | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 8,449 | — | — | Form 4 |
| 2026-08-07 | Saccomano Nicholas A | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 8,449 | — | — | Form 4 |
| 2026-08-07 | Saccomano Nicholas A | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 1,485 | — | — | Form 4 |
| 2026-08-07 | Saccomano Nicholas A | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 1,485 | — | — | Form 4 |
| 2026-08-07 | Saccomano Nicholas A | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 2,359 | — | — | Form 4 |
| 2026-08-07 | Saccomano Nicholas A | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 2,359 | — | — | Form 4 |
| 2026-08-07 | Saccomano Nicholas A | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 150,000 | — | $0 | Form 4 |
| 2026-08-07 | Carruthers R Michael | Director | Grant / award / vesting (derivative) | 22,350 | — | $0 | Form 4 |
| 2026-08-07 | GREY MICHAEL G | Director | Grant / award / vesting (derivative) | 22,350 | — | $0 | Form 4 |
| 2026-08-07 | Jansen Valerie Malyvanh | Director | Grant / award / vesting (derivative) | 22,350 | — | $0 | Form 4 |
| 2026-08-07 | Manke Isaac | Director | Grant / award / vesting (derivative) | 15,300 | — | — | Form 4 |
| 2026-08-07 | Manke Isaac | Director | Disposition to the issuer (derivative) | 15,300 | — | — | Form 4 |
| 2026-08-07 | Manke Isaac | Director | Grant / award / vesting (derivative) | 300,000 | — | $0 | Form 4 |
| 2026-08-07 | Phillips Andrew John | Director | Grant / award / vesting (derivative) | 22,350 | — | $0 | Form 4 |
| 2026-08-07 | Ratcliffe Liam | Director | Grant / award / vesting (derivative) | 22,350 | — | $0 | Form 4 |
| 2026-08-07 | Mathers Edward T | Director | Grant / award / vesting (derivative) | 22,350 | — | $0 | Form 4 |
| 2026-06-22 | Leverone Jason A. | Officer (Chief Financial Officer) | Open-market sale | 303 | $4.40 | $1.3K | Form 4 |
| 2026-06-22 | Saccomano Nicholas A | Director, Officer (President and CEO) | Open-market sale | 86 | $4.40 | $378 | Form 4 |
| 2026-06-04 | Carruthers R Michael | Director | Grant / award / vesting (derivative) | 7,650 | — | $0 | Form 4 |
| 2026-06-04 | GREY MICHAEL G | Director | Grant / award / vesting (derivative) | 7,650 | — | $0 | Form 4 |
| 2026-06-04 | Jansen Valerie Malyvanh | Director | Grant / award / vesting (derivative) | 7,650 | — | $0 | Form 4 |
| 2026-06-04 | Phillips Andrew John | Director | Grant / award / vesting (derivative) | 7,650 | — | $0 | Form 4 |
| 2026-06-04 | Ratcliffe Liam | Director | Grant / award / vesting (derivative) | 1,275 | — | $0 | Form 4 |
| 2026-06-04 | Mathers Edward T | Director | Grant / award / vesting (derivative) | 7,650 | — | $0 | Form 4 |
| 2026-04-01 | Hartley Dylan | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 110,000 | — | $0 | Form 4 |
| 2026-04-01 | Leverone Jason A. | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 110,000 | — | $0 | Form 4 |
| 2026-04-01 | Saccomano Nicholas A | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 330,000 | — | $0 | Form 4 |
Ask the chat about OKUR's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ONKURE THERAPEUTICS INC CLASS A (OKUR).
Last updated 2026-09-21 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.